Can CVS Health (CVS) Still Look Cheap After A 50% Run?

CVS Health has delivered a strong 49.8% gain over the past three years, yet its valuation checks still point to a stock that looks cheap on broad measures rather than fully priced in after the run.

• The 49.8% share price gain over three years suggests investors have already rewarded CVS Health for progress in the business, so the question is how much upside is left from here.
• Recent bullish analyst commentary that highlights recovery at Aetna and the potential return of share buybacks can support sentiment, while any disappointment around future earnings power or capital returns may pressure what investors are willing to pay.
• A high value score of 5.0 indicates that on most of the key valuation checks, CVS Health leans inexpensive rather than expensive.

For investors, the debate is whether CVS Health's current share price still offers an attractive entry point, given that blend of past gains and an overall cheap valuation signal.

Amplify the kind of value story you see in CVS Health by scanning a curated list of 31 high quality undervalued stocks that pair solid fundamentals with potentially appealing price tags.

Is CVS Health a Bargain on Earnings?

P/E works well for CVS Health because earnings power sits at the center of how investors judge a mature healthcare group with multiple business lines. The stock currently trades on a P/E of 24.8x, which lines up almost exactly with the broader healthcare sector average near 24.8x. Against a peer set that clusters around 18.8x, the stock looks more expensive on a simple like for like comparison.

The valuation model used here points to a fair P/E of 37.2x for CVS Health, which is materially higher than where the shares trade today. That gap suggests the current earnings multiple reflects a more cautious view of the company than this framework implies, even after the recent rally on bullish analyst commentary. This check indicates CVS Health appears undervalued on its P/E multiple relative to the level the model identifies as fair.

See what the numbers say about this price — find out in our valuation breakdown.

The CVS Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CVS Health pick up where the valuation puzzle leaves off by spelling out which paths for growth, profitability and earnings would need to play out for the current share price to look low or demanding. Each scenario ties its number to a clear view on how CVS Health's revenue mix, margins and risk profile could evolve, giving you a reference point to revisit as fresh information comes through.

One of the top community narratives on CVS Health: 9% undervalued

"CVS Health is rebuilding itself while still operating at full scale, a difficult balancing act that has weighed on investor confidence..."

Read one of the top narratives on CVS Health

Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!

The Bottom Line

For CVS Health, the current picture leans toward undervalued on market multiples, yet not in a way that removes the need for judgment. The valuation work suggests investors are not paying a premium price for the existing earnings profile, even after the past three year return. What really separates bulls and bears now is whether the earnings engine behind that P/E can stabilise and improve as the business reshapes Aetna, reins in risk, and decides how aggressively to return capital. If profitability proves durable and execution issues stay contained, the current discount starts to look more like an opportunity than a warning.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com